Therapeutic Inducers of Apoptosis in Ovarian Cancer
Abstract
:1. Apoptosis in Ovarian Cancer
2. Direct Targets in Apoptotic Pathways
2.1. BCL-Protein Inhibitors
2.2. IAPs Inhibitors
3. Indirect Cellular Processes that Affect Apoptosis Induction
3.1. Homologous Recombination
3.2. p53 Mutation
3.3. Micro-RNAs in Inducing Apoptosis
4. Targeting Cancer-Associated Pathways to Induce Apoptosis
4.1. JAK/STAT3 Pathway
4.2. WNT/β-Catenin Pathway
4.3. MET/HGF Pathway
4.4. MAPK/ERK Pathway
4.5. PI3K/AKT/mTOR Pathway
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Vaughan, S.; Coward, J.I.; Bast, R.C.; Berchuck, A.; Berek, J.S.; Brenton, J.D.; Coukos, G.; Crum, C.C.; Drapkin, R.; Etemadmoghadam, D.; et al. Rethinking ovarian cancer: Recommendations for improving outcomes. Nat. Rev. Cancer 2011, 11, 719–725. [Google Scholar] [CrossRef] [PubMed]
- Berek, J.S.; Crum, C.; Friedlander, M. Cancer of the ovary, fallopian tube, and peritoneum. Int. J. Gynecol. Obstet. 2012, 119, S118–S129. [Google Scholar] [CrossRef]
- Smith, R.A.; Manassaram-Baptiste, D.; Brooks, D.; Cokkinides, V.; Doroshenk, M.; Saslow, D.; Wender, R.C.; Brawley, O.W. Cancer screening in the United States, 2014: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J. Clin. 2014, 64, 30–51. [Google Scholar] [CrossRef] [PubMed]
- Jayson, G.C.; Kohn, E.C.; Kitchener, H.C.; Ledermann, J.A. Ovarian cancer. Lancet 2014, 384, 1376–1388. [Google Scholar] [CrossRef]
- Shahzad, M.M.; Lopez-Berestein, G.; Sood, A.K. Novel strategies for reversing platinum resistance. Drug Resist. Updat. 2009, 12, 148–152. [Google Scholar] [CrossRef]
- Wong, R.S. Apoptosis in cancer: From pathogenesis to treatment. J. Exp. Clin. Cancer Res. 2011, 30, 87. [Google Scholar] [CrossRef]
- Szegezdi, E.; Fitzgerald, U.; Samali, A. Caspase-12 and ER-stress-mediated apoptosis: The story so far. Ann. N. Y. Acad. Sci. 2003, 1010, 186–194. [Google Scholar] [CrossRef]
- Danial, N.N.; Korsmeyer, S.J. Cell death: Critical control points. Cell 2004, 116, 205–219. [Google Scholar] [CrossRef]
- Tsujimoto, Y.; Finger, L.; Yunis, J.; Nowell, P.; Croce, C. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science 1984, 226, 1097–1099. [Google Scholar] [CrossRef]
- Hengartner, M.O. Apoptosis: Corralling the corpses. Cell 2001, 104, 325–328. [Google Scholar] [CrossRef]
- Igney, F.H.; Krammer, P.H. Death and anti-death: Tumour resistance to apoptosis. Nat. Rev. Cancer 2002, 2, 277–288. [Google Scholar] [CrossRef] [PubMed]
- Castells, M.; Milhas, D.; Gandy, C.; Thibault, B.; Rafii, A.; Delord, J.-P.; Couderc, B. Microenvironment mesenchymal cells protect ovarian cancer cell lines from apoptosis by inhibiting XIAP inactivation. Cell Death Dis. 2013, 4, e887. [Google Scholar] [CrossRef] [PubMed]
- Rada, M.; Nallanthighal, S.; Cha, J.; Ryan, K.; Sage, J.; Eldred, C.; Ullo, M.; Orsulic, S.; Cheon, D.-J. Inhibitor of apoptosis proteins (IAPs) mediate collagen type XI alpha 1-driven cisplatin resistance in ovarian cancer. Oncogene 2018, 37, 4809–4820. [Google Scholar] [CrossRef] [PubMed]
- Pileczki, V.; Cojocneanu-Petric, R.; Maralani, M.; Neagoe, I.B.; Săndulescu, R. MicroRNAs as regulators of apoptosis mechanisms in cancer. Clujul Med. 2016, 89, 50–55. [Google Scholar] [CrossRef] [PubMed]
- Yang, H.; He, L.; Kruk, P.; Nicosia, S.V.; Cheng, J.Q. Expression of Concern: “Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells”. Int. J. Cancer 2019, 144, E8. [Google Scholar]
- Chipuk, J.E.; Moldoveanu, T.; Llambi, F.; Parsons, M.J.; Green, D.R. The BCL-2 family reunion. Mol. Cell 2010, 37, 299–310. [Google Scholar] [CrossRef]
- Labi, V.; Grespi, F.; Baumgartner, F.; Villunger, A. Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: A breakthrough in anticancer therapy? Cell Death Differ. 2008, 15, 977–987. [Google Scholar] [CrossRef]
- Davids, M.S.; Letai, A. Targeting the B-cell lymphoma/leukemia 2 family in cancer. J. Clin. Oncol. 2012, 30, 3127–3135. [Google Scholar] [CrossRef]
- Moldoveanu, T.; Follis, A.V.; Kriwacki, R.W.; Green, D.R. Many players in BCL-2 family affairs. Trends Biochem. Sci. 2014, 39, 101–111. [Google Scholar] [CrossRef]
- Luna-Vargas, M.P.; Chipuk, J.E. The deadly landscape of pro-apoptotic BCL-2 proteins in the outer mitochondrial membrane. FEBS J. 2016, 283, 2676–2689. [Google Scholar] [CrossRef]
- Sarosiek, K.A.; Ni Chonghaile, T.; Letai, A. Mitochondria: Gatekeepers of response to chemotherapy. Trends Cell Biol. 2013, 23, 612–619. [Google Scholar] [CrossRef] [PubMed]
- Shamas-Din, A.; Kale, J.; Leber, B.; Andrews, D.W. Mechanisms of Action of Bcl-2 Family Proteins. Cold Spring Harb. Perspect. Biol. 2013, 5, a008714. [Google Scholar] [CrossRef] [PubMed]
- Andreu-Fernandez, V.; Sancho, M.; Genovés, A.; Lucendo, E.; Todt, F.; Lauterwasser, J.; Funk, K.; Jahreis, G.; Pérez-Payá, E.; Mingarro, I.; et al. Bax transmembrane domain interacts with prosurvival Bcl-2 proteins in biological membranes. Proc. Natl. Acad. Sci. USA 2017, 114, 310–315. [Google Scholar] [CrossRef] [PubMed]
- Barclay, L.A.; Wales, T.E.; Garner, T.P.; Wachter, F.; Lee, S.; Guerra, R.M.; Stewart, M.L.; Braun, C.R.; Bird, G.H.; Gavathiotis, E.; et al. Inhibition of Pro-apoptotic BAX by a noncanonical interaction mechanism. Mol. Cell 2015, 57, 873–886. [Google Scholar] [CrossRef] [PubMed]
- Akl, H.; Vervloessem, T.; Kiviluoto, S.; Bittremieux, M.; Parys, J.B.; De Smedt, H.; Bultynck, G. A dual role for the anti-apoptotic Bcl-2 protein in cancer: Mitochondria versus endoplasmic reticulum. Biochim. Biophys. Acta Bioenerg. 2014, 1843, 2240–2252. [Google Scholar] [CrossRef] [PubMed]
- Peperzak, V.; Slinger, E.; Ter Burg, J.; Eldering, E. Functional disparities among BCL-2 members in tonsillar and leukemic B-cell subsets assessed by BH3-mimetic profiling. Cell Death Differ. 2017, 24, 111–119. [Google Scholar] [CrossRef]
- Pan, R.; Hogdal, L.J.; Benito, J.M.; Bucci, D.; Han, L.; Borthakur, G.; Cortes, J.; DeAngelo, D.J.; Debose, L.; Mu, H.; et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014, 4, 362–375. [Google Scholar] [CrossRef]
- Moore, V.D.G.; Schlis, K.D.; Sallan, S.E.; Armstrong, S.A.; Letai, A. BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood 2008, 111, 2300–2309. [Google Scholar] [CrossRef]
- Dai, Y.; Jin, S.; Li, X.; Wang, D. The involvement of Bcl-2 family proteins in AKT-regulated cell survival in cisplatin resistant epithelial ovarian cancer. Oncotarget 2017, 8, 1354–1368. [Google Scholar] [CrossRef]
- Amundson, S.A.; Myers, T.G.; Scudiero, D.; Kitada, S.; Reed, J.C.; Fornace, A.J. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res. 2000, 60, 6101–6110. [Google Scholar]
- Wong, M.; Tan, N.; Zha, J.; Peale, F.V.; Yue, P.; Fairbrother, W.J.; Belmont, L.D. Navitoclax (ABT-263) Reduces Bcl-xL–Mediated Chemoresistance in Ovarian Cancer Models. Mol. Cancer Ther. 2012, 11, 1026–1035. [Google Scholar] [CrossRef] [PubMed]
- Witham, J.; Valenti, M.R.; De-Haven-Brandon, A.K.; Vidot, S.; Eccles, S.A.; Kaye, S.B.; Richardson, A. The Bcl-2/Bcl-XL Family Inhibitor ABT-737 Sensitizes Ovarian Cancer Cells to Carboplatin. Clin. Cancer Res. 2007, 13, 7191–7198. [Google Scholar] [CrossRef] [PubMed]
- De Wolf, E.; de Wolf, C.; Richardson, A. ABT-737 and pictilisib synergistically enhance pitavastatin-induced apoptosis in ovarian cancer cells. Oncol. Lett. 2018, 15, 1979–1984. [Google Scholar] [CrossRef] [PubMed]
- Mohammad, R.M.; Goustin, A.S.; Aboukameel, A.; Chen, B.; Banerjee, S.; Wang, G.; Nikolovska-Coleska, Z.; Wang, S.; Al-Katib, A. Preclinical Studies of TW-37, a New Nonpeptidic Small-Molecule Inhibitor of Bcl-2, in Diffuse Large Cell Lymphoma Xenograft Model Reveal Drug Action on Both Bcl-2 and Mcl-1. Clin. Cancer Res. 2007, 13, 2226–2235. [Google Scholar] [CrossRef] [PubMed]
- Wang, H.; Zhang, Z.; Wei, X.; Dai, R. Small-molecule inhibitor of Bcl-2 (TW-37) suppresses growth and enhances cisplatin-induced apoptosis in ovarian cancer cells. J. Ovarian Res. 2015, 8, 3. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- De Almagro, M.C.; Vucic, D. The inhibitor of apoptosis (IAP) proteins are critical regulators of signaling pathways and targets for anti-cancer therapy. Exp. Oncol. 2012, 34, 200–211. [Google Scholar] [PubMed]
- Trédan, O.; Galmarini, C.M.; Patel, K.; Tannock, I.F. Drug Resistance and the Solid Tumor Microenvironment. J. Natl. Cancer Inst. 2007, 99, 1441–1454. [Google Scholar] [CrossRef] [Green Version]
- Benetatos, C.A.; Mitsuuchi, Y.; Burns, J.M.; Neiman, E.M.; Condon, S.M.; Yu, G.; Seipel, M.E.; Kapoor, G.S.; Laporte, M.G.; Rippin, S.R.; et al. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-kappaB activation, and is active in patient-derived xenograft models. Mol. Cancer Ther. 2014, 13, 867–879. [Google Scholar] [CrossRef]
- Petrucci, E.; Pasquini, L.; Bernabei, M.; Saulle, E.; Biffoni, M.; Accarpio, F.; Sibio, S.; di Giorgio, A.; di Donato, V.; Casorelli, A.; et al. A Small Molecule SMAC Mimic LBW242 Potentiates TRAIL- and Anticancer Drug-Mediated Cell Death of Ovarian Cancer Cells. PLoS ONE 2012, 7, e35073. [Google Scholar] [CrossRef] [Green Version]
- Sun, H.; Lu, J.; Liu, L.; Yang, C.-Y.; Wang, S. Potent and Selective Small-Molecule Inhibitors of cIAP1/2 Proteins Reveal That the Binding of Smac Mimetics to XIAP BIR3 Is Not Required for Their Effective Induction of Cell Death in Tumor Cells. ACS Chem. Biol. 2014, 9, 994–1002. [Google Scholar] [CrossRef]
- Samuel, T.; Welsh, K.; Lober, T.; Togo, S.H.; Zapata, J.M.; Reed, J.C. Distinct BIR domains of cIAP1 mediate binding to and ubiquitination of tumor necrosis factor receptor-associated factor 2 and second mitochondrial activator of caspases. J. Biol. Chem. 2006, 281, 1080–1090. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gyrd-Hansen, M.; Meier, P. IAPs: From caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat. Rev. Cancer 2010, 10, 561–574. [Google Scholar] [CrossRef] [PubMed]
- Holcik, M.; Gibson, H.; Korneluk, R.G. XIAP: Apoptotic brake and promising therapeutic target. Apoptosis 2001, 6, 253–261. [Google Scholar] [CrossRef] [PubMed]
- Sui, L.; Dong, Y.; Ohno, M.; Watanabe, Y.; Sugimoto, K.; Tokuda, M. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors. Int. J. Oncol. 2002, 21, 315–320. [Google Scholar] [CrossRef]
- Mansouri, A.; Zhang, Q.; Ridgway, L.D.; Tian, L.; Claret, F.-X. Cisplatin Resistance in an Ovarian Carcinoma Is Associated with a Defect in Programmed Cell Death Control Through XIAP Regulation. Oncol. Res. 2003, 13, 399–404. [Google Scholar] [CrossRef] [Green Version]
- Sasaki, H.; Sheng, Y.; Kotsuji, F.; Tsang, B.K. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res. 2000, 60, 5659–5666. [Google Scholar]
- Yang, X.; Xing, H.; Gao, Q.; Chen, G.; Lu, Y.; Wang, S.; Ma, D. Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells. Gynecol. Oncol. 2005, 97, 413–421. [Google Scholar] [CrossRef]
- Ma, J.-J.; Chen, B.-L.; Xin, X.-Y. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma. Eur. J. Obstet. Gynecol. Reprod. Biol. 2009, 146, 222–226. [Google Scholar] [CrossRef]
- Chen, X.; Gong, L.; Ou, R.; Zheng, Z.; Chen, J.; Xie, F.; Huang, X.; Qiu, J.; Zhang, W.; Jiang, Q.; et al. Sequential combination therapy of ovarian cancer with cisplatin and gamma-secretase inhibitor MK-0752. Gynecol. Oncol. 2016, 140, 537–544. [Google Scholar] [CrossRef]
- Shen, W.; Liang, B.; Yin, J.; Li, X.; Cheng, J. Noscapine Increases the Sensitivity of Drug-Resistant Ovarian Cancer Cell Line SKOV3/DDP to Cisplatin by Regulating Cell Cycle and Activating Apoptotic Pathways. Cell Biochem. Biophys. 2015, 72, 203–213. [Google Scholar] [CrossRef]
- Janzen, D.M.; Tiourin, E.; Salehi, J.A.; Paik, D.Y.; Lu, J.; Pellegrini, M.; Memarzadeh, S. An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer. Nat. Commun. 2015, 6. [Google Scholar] [CrossRef] [PubMed]
- La, V.; Fujikawa, R.; Janzen, D.; Bainvoll, L.; Nunez, M.; Memarzadeh, S. Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy. NPJ Precis. Oncol. 2017, 1. [Google Scholar] [CrossRef]
- Liu, Y.; Tong, L.; Luo, Y.; Li, X.; Chen, G.; Wang, Y. Resveratrol inhibits the proliferation and induces the apoptosis in ovarian cancer cells via inhibiting glycolysis and targeting AMPK/mTOR signaling pathway. J. Cell. Biochem. 2018, 119, 6162–6172. [Google Scholar] [CrossRef] [PubMed]
- Thibault, B.; Genre, L.; le Naour, A.; Broca, C.; Mery, E.; Vuagniaux, G.; Delord, J.P.; Wiedemann, N.; Couderc, B. DEBIO 1143, an IAP inhibitor, reverses carboplatin resistance in ovarian cancer cells and triggers apoptotic or necroptotic cell death. Sci. Rep. 2018, 8. [Google Scholar] [CrossRef] [PubMed]
- Hurwitz, H.I.; Smith, D.C.; Pitot, H.C.; Brill, J.M.; Chugh, R.; Rouits, E.; Rubin, J.; Strickler, J.; Vuagniaux, G.; Sorensen, J.M.; et al. Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: Results of a first-in-man study. Cancer Chemother. Pharmacol. 2015, 75, 851–859. [Google Scholar] [CrossRef] [Green Version]
- Brunckhorst, M.K.; Lerner, D.; Wang, S.; Yu, Q. AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins, inhibits progression of human ovarian cancer. Cancer Biol. Ther. 2012, 13, 804–811. [Google Scholar] [CrossRef] [Green Version]
- Cai, Q.; Sun, H.; Peng, Y.; Lu, J.; Nikolovska-Coleska, Z.; McEachern, D.; Liu, L.; Qiu, S.; Yang, C.-Y.; Miller, R.; et al. A Potent and Orally Active Antagonist (SM-406/AT-406) of Multiple Inhibitor of Apoptosis Proteins (IAPs) in Clinical Development for Cancer Treatment. J. Med. Chem. 2011, 54, 2714–2726. [Google Scholar] [CrossRef] [Green Version]
- Zhang, T.; Li, Y.; Zou, P.; Yu, J.-Y.; McEachern, D.; Wang, S.; Sun, D. Physiologically based pharmacokinetic and pharmacodynamic modeling of an antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in a mouse xenograft model of human breast cancer. Biopharm. Drug Dispos. 2013, 34, 348–359. [Google Scholar] [CrossRef] [Green Version]
- Liu, J.F.; Konstantinopoulos, P.A.; Matulonis, U.A. PARP inhibitors in ovarian cancer: Current status and future promise. Gynecol. Oncol. 2014, 133, 362–369. [Google Scholar] [CrossRef]
- Takaoka, M.; Miki, Y. BRCA1 gene: Function and deficiency. Int. J. Clin. Oncol. 2018, 23, 36–44. [Google Scholar] [CrossRef]
- Abaji, C.; Cousineau, I.; Belmaaza, A. BRCA2 Regulates Homologous Recombination in Response to DNA Damage: Implications for Genome Stability and Carcinogenesis. Cancer Res. 2005, 65, 4117–4125. [Google Scholar] [CrossRef] [PubMed]
- The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474, 609–615. [Google Scholar] [CrossRef] [PubMed]
- Konstantinopoulos, P.A.; Spentzos, D.; Karlan, B.Y.; Taniguchi, T.; Fountzilas, E.; Francoeur, N.; Levine, D.A.; Cannistra, S.A. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J. Clin. Oncol. 2010, 28, 3555–3561. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Norquist, B.; Wurz, K.A.; Pennil, C.C.; Garcia, R.; Gross, J.; Sakai, W.; Karlan, B.Y.; Taniguchi, T.; Swisher, E.M. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J. Clin. Oncol. 2011, 29, 3008–3015. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tutt, A.; Tovey, H.; Cheang, M.C.U.; Kernaghan, S.; Kilburn, L.; Gazinska, P.; Owen, J.; Abraham, J.; Barrett, S.; Barrett-Lee, P.; et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: The TNT Trial. Nat. Med. 2018, 24, 628–637. [Google Scholar] [CrossRef] [Green Version]
- Wiedemeyer, W.R.; Beach, J.A.; Karlan, B.Y. Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System. Front. Oncol. 2014, 4, 34. [Google Scholar] [CrossRef] [Green Version]
- Wilson, A.J.; Stubbs, M.; Liu, P.; Ruggeri, B.; Khabele, D. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer. Gynecol. Oncol. 2018, 149, 575–584. [Google Scholar] [CrossRef]
- Goundiam, O.; Gestraud, P.; Popova, T.; Rouge, T.D.L.M.; Fourchotte, V.; Gentien, D.; Hupé, P.; Becette, V.; Houdayer, C.; Roman-Roman, S.; et al. Histo-genomic stratification reveals the frequent amplification/overexpression of CCNE 1 and BRD 4 genes in non-BRCAness high grade ovarian carcinoma. Int. J. Cancer 2015, 137, 1890–1900. [Google Scholar] [CrossRef]
- Ucar, D.; Lin, D.I. Amplification of the bromodomain-containing protein 4 gene in ovarian high-grade serous carcinoma is associated with worse prognosis and survival. Mol. Clin. Oncol. 2015, 3, 1291–1294. [Google Scholar] [CrossRef] [Green Version]
- Jiang, Z.; Fletcher, N.M.; Ali-Fehmi, R.; Diamond, M.P.; Abu-Soud, H.M.; Munkarah, A.R.; Saed, G.M. Modulation of redox signaling promotes apoptosis in epithelial ovarian cancer cells. Gynecol. Oncol. 2011, 122, 418–423. [Google Scholar] [CrossRef] [Green Version]
- Havrilesky, L.; Darcy, K.M.; Hamdan, H.; Priore, R.L.; Leon, J.; Bell, J.; Berchuck, A. Gynecologic Oncology Group Study. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: A Gynecologic Oncology Group Study. J. Clin. Oncol. 2003, 21, 3814–3825. [Google Scholar] [CrossRef] [PubMed]
- Risch, H.A.; McLaughlin, J.R.; Cole, D.E.C.; Rosen, B.; Bradley, L.; Fan, I.; Tang, J.; Li, S.; Zhang, S.; Shaw, P.A.; et al. Population BRCA1 and BRCA2 Mutation Frequencies and Cancer Penetrances: A Kin–Cohort Study in Ontario, Canada. J. Natl. Cancer Inst. 2006, 98, 1694–1706. [Google Scholar] [CrossRef] [PubMed]
- Kang, H.J.; Chun, S.-M.; Kim, K.-R.; Sohn, I.; Sung, C.O. Clinical Relevance of Gain-Of-Function Mutations of p53 in High-Grade Serous Ovarian Carcinoma. PLoS ONE 2013, 8, e72609. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Giaccia, A.J.; Kastan, M.B. The complexity of p53 modulation: Emerging patterns from divergent signals. Genome Res. 1998, 12, 2973–2983. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nakano, K.; Vousden, K.H. PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell 2001, 7, 683–694. [Google Scholar] [CrossRef]
- Oda, E. Noxa, a BH3-Only Member of the Bcl-2 Family and Candidate Mediator of p53-Induced Apoptosis. Science 2000, 288, 1053–1058. [Google Scholar] [CrossRef]
- Robles, A.I.; Bemmels, N.A.; Foraker, A.B.; Harris, C.C. APAF-1 is a transcriptional target of p53 in DNA damage-induced apoptosis. Cancer Res. 2001, 61, 6660–6664. [Google Scholar]
- Di Agostino, S.; Strano, S.; Emiliozzi, V.; Zerbini, V.; Mottolese, M.; Sacchi, A.; Blandino, G.; Piaggio, G. Gain of function of mutant p53: The mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 2006, 10, 191–202. [Google Scholar] [CrossRef] [Green Version]
- Blandino, G.; Levine, A.J.; Oren, M. Mutant p53 gain of function: Differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 1999, 18, 477–485. [Google Scholar] [CrossRef] [Green Version]
- Reles, A.; Wen, W.H.; Schmider, A.; Gee, C.; Runnebaum, I.B.; Kilian, U.; Jones, L.A.; El-Naggar, A.; Minguillon, C.; Schönborn, I.; et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin. Cancer Res. 2001, 7, 2984–2997. [Google Scholar]
- Shelling, A.N. Role of p53 in drug resistance in ovarian cancer. Lancet 1997, 349, 744–745. [Google Scholar] [CrossRef]
- Buttitta, F.; Marchetti, A.; Gadducci, A.; Pellegrini, S.; Morganti, M.; Carnicelli, V.; Cosio, S.; Gagetti, O.; Genazzani, A.; Bevilacqua, G. p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: A molecular and immunohistochemical study. Br. J. Cancer 1997, 75, 230–235. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Peng, X.; Zhang, M.-Q.-Z.; Conserva, F.; Hosny, G.; Selivanova, G.; Bykov, V.J.N.; Arnér, E.S.J.; Wiman, K.G. APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell Death Dis. 2013, 4, e881. [Google Scholar] [CrossRef] [PubMed]
- Issaeva, N.; Bozko, P.; Enge, M.; Protopopova, M.; Verhoef, L.G.G.C.; Masucci, M.; Pramanik, A.; Selivanova, G. Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors. Nat. Med. 2004, 10, 1321–1328. [Google Scholar] [CrossRef]
- Russo, D.; Ottaggio, L.; Penna, I.; Foggetti, G.; Fronza, G.; Inga, A.; Menichini, P. PRIMA-1 cytotoxicity correlates with nucleolar localization and degradation of mutant p53 in breast cancer cells. Biochem. Biophys. Res. Commun. 2010, 402, 345–350. [Google Scholar] [CrossRef]
- Roh, J.L.; Kang, S.K.; Minn, I.; Califano, J.A.; Sidransky, D.; Koch, W.M. p53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma. Oral. Oncol. 2011, 47, 8–15. [Google Scholar] [CrossRef] [Green Version]
- Lehmann, S.; Bykov, V.N.; Ali, D.; Andrén, O.; Cherif, H.; Tidefelt, U.; Uggla, B.; Yachnin, J.; Juliusson, G.; Moshfegh, A.; et al. Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer. J. Clin. Oncol. 2012, 30, 3633–3639. [Google Scholar] [CrossRef]
- Yoshikawa, N.; Kajiyama, H.; Nakamura, K.; Utsumi, F.; Niimi, K.; Mitsui, H.; Sekiya, R.; Suzuki, S.; Shibata, K.; Callen, D.; et al. PRIMA-1MET induces apoptosis through accumulation of intracellular reactive oxygen species irrespective of p53 status and chemo-sensitivity in epithelial ovarian cancer cells. Oncol. Rep. 2016, 35, 2543–2552. [Google Scholar] [CrossRef] [Green Version]
- He, L.; Hannon, G.J. MicroRNAs: Small RNAs with a big role in gene regulation. Nat. Rev. Genet. 2004, 5, 522–531. [Google Scholar] [CrossRef]
- Zamore, P.D. Ribo-gnome: The Big World of Small RNAs. Science 2005, 309, 1519–1524. [Google Scholar] [CrossRef] [Green Version]
- Miska, E.A. How microRNAs control cell division, differentiation and death. Curr. Opin. Genet. Dev. 2005, 15, 563–568. [Google Scholar] [CrossRef] [PubMed]
- Johnson, S.M.; Grosshans, H.; Shingara, J.; Byrom, M.; Jarvis, R.; Cheng, A.; Labourier, E.; Reinert, K.L.; Brown, D.; Slack, F.J. RAS Is Regulated by the let-7 MicroRNA Family. Cell 2005, 120, 635–647. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mayr, C.; Hemann, M.T.; Bartel, D.P. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 2007, 315, 1576–1579. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lee, Y.S.; Dutta, A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genome Res. 2007, 21, 1025–1030. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cimmino, A.; Calin, G.A.; Fabbri, M.; Iorio, M.V.; Ferracin, M.; Shimizu, M.; Wojcik, S.E.; Aqeilan, R.I.; Zupo, S.; Dono, M.; et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. USA 2005, 102, 13944–13949. [Google Scholar] [CrossRef] [Green Version]
- Di Leva, G.; Croce, C.M. The Role of microRNAs in the Tumorigenesis of Ovarian Cancer. Front. Oncol. 2013, 3, 153. [Google Scholar] [CrossRef] [Green Version]
- Iorio, M.V.; Visone, R.; Di Leva, G.; Donati, V.; Petrocca, F.; Casalini, P.; Taccioli, C.; Volinia, S.; Liu, C.-G.; Alder, H.; et al. MicroRNA Signatures in Human Ovarian Cancer. Cancer Res. 2007, 67, 8699–8707. [Google Scholar] [CrossRef] [Green Version]
- Lu, Y.; Yue, X.; Cui, Y.; Zhang, J.; Wang, K. MicroRNA-124 suppresses growth of human hepatocellular carcinoma by targeting STAT3. Biochem. Biophys. Res. Commun. 2013, 441, 873–879. [Google Scholar] [CrossRef]
- Zheng, Y.-B.; Xiao, G.-C.; Tong, S.-L.; Ding, Y.; Wang, Q.-S.; Li, S.-B.; Hao, Z.-N. Paeoniflorin inhibits human gastric carcinoma cell proliferation through up-regulation of microRNA-124 and suppression of PI3K/Akt and STAT3 signaling. World J. Gastroenterol. 2015, 21, 7197–7207. [Google Scholar] [CrossRef]
- Zhang, Y.; Zheng, L.; Huang, J.; Gao, F.; Lin, X.; He, L.; Li, D.; Li, Z.; Ding, Y.; Chen, L. MiR-124 Radiosensitizes Human Colorectal Cancer Cells by Targeting PRRX1. PLoS ONE 2014, 9, e93917. [Google Scholar] [CrossRef]
- Zhang, W.; Mao, Y.-Q.; Wang, H.; Yin, W.-J.; Zhu, S.-X.; Wang, W.-C. MiR-124 suppresses cell motility and adhesion by targeting talin 1 in prostate cancer cells. Cancer Cell Int. 2015, 15, 49. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vecchione, A.; Belletti, B.; Lovat, F.; Volinia, S.; Chiappetta, G.; Giglio, S.; Sonego, M.; Cirombella, R.; Onesti, E.C.; Pellegrini, P.; et al. A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. Proc. Natl. Acad. Sci. USA 2013, 110, 9845–9850. [Google Scholar] [CrossRef] [Green Version]
- Shi, X.B.; Xue, L.; Ma, A.H.; Tepper, C.G.; Gandour-Edwards, R.; Kung, H.J.; deVere White, R.W. Tumor suppressive miR-124 targets androgen receptor and inhibits proliferation of prostate cancer cells. Oncogene 2013, 32, 4130–4138. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, P.; Chen, L.; Zhang, J.; Chen, H.; Fan, J.; Wang, K.; Luo, J.; Chen, Z.; Meng, Z.; Liu, L. Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1. Oncogene 2014, 33, 514–524. [Google Scholar] [CrossRef] [PubMed]
- Zheng, F.; Liao, Y.J.; Cai, M.Y.; Liu, Y.H.; Liu, T.H.; Chen, S.P.; Bian, X.W.; Guan, X.Y.; Lin, M.C.; Zeng, Y.X.; et al. The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH3. Gut 2012, 61, 278–289. [Google Scholar] [CrossRef] [PubMed]
- Liang, Y.J.; Wang, Q.Y.; Zhou, C.X.; Yin, Q.Q.; He, M.; Yu, X.T.; Cao, D.X.; Chen, G.Q.; He, J.R.; Zhao, Q. MiR-124 targets Slug to regulate epithelial-mesenchymal transition and metastasis of breast cancer. Carcinogenesis 2013, 34, 713–722. [Google Scholar] [CrossRef]
- Xia, J.; Wu, Z.; Yu, C.; He, W.; Zheng, H.; He, Y.; Jian, W.; Chen, L.; Zhang, L.; Li, W. miR-124 inhibits cell proliferation in gastric cancer through down-regulation of SPHK1. J. Pathol. 2012, 227, 470–480. [Google Scholar] [CrossRef]
- Milstien, S.; Spiegel, S. Targeting sphingosine-1-phosphate: A novel avenue for cancer therapeutics. Cancer Cell 2006, 9, 148–150. [Google Scholar] [CrossRef] [Green Version]
- Fuereder, T.; Hoeflmayer, D.; Jaeger-Lansky, A.; Rasin-Streden, D.; Strommer, S.; Fisker, N.; Hansen, B.J.; Crevenna, R.; Wacheck, V. Sphingosine kinase 1 is a relevant molecular target in gastric cancer. Anti-Cancer Drugs 2011, 22, 245–252. [Google Scholar] [CrossRef]
- Zhang, H.; Wang, Q.; Zhao, Q.; Di, W. MiR-124 inhibits the migration and invasion of ovarian cancer cells by targeting SphK1. J. Ovarian Res. 2013, 6, 84. [Google Scholar] [CrossRef] [Green Version]
- Yuan, L.; Li, S.; Zhou, Q.; Wang, D.; Zou, D.; Shu, J.; Huang, Y. MiR-124 inhibits invasion and induces apoptosis of ovarian cancer cells by targeting programmed cell death 6. Oncol. Lett. 2017, 14, 7311–7317. [Google Scholar] [CrossRef] [PubMed]
- La Cour, J.M.; Høj, B.R.; Mollerup, J.; Simon, R.; Sauter, G.; Berchtold, M.W. The apoptosis linked gene ALG-2 is dysregulated in tumors of various origin and contributes to cancer cell viability. Mol. Oncol. 2008, 1, 431–439. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mahul-Mellier, A.-L.; Strappazzon, F.; Petiot, A.; Chatellard-Causse, C.; Torch, S.; Blot, B.; Freeman, K.; Kuhn, L.; Garin, J.; Verna, J.-M.; et al. Alix and ALG-2 are involved in tumor necrosis factor receptor 1-induced cell death. J. Biol. Chem. 2008, 283, 34954–34965. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ibarra, I.; Erlich, Y.; Muthuswamy, S.K.; Sachidanandam, R.; Hannon, G.J. A role for microRNAs in maintenance of mouse mammary epithelial progenitor cells. Genome Res. 2007, 21, 3238–3243. [Google Scholar] [CrossRef] [Green Version]
- Johnson, C.D.; Esquela-Kerscher, A.; Stefani, G.; Byrom, M.; Kelnar, K.; Ovcharenko, D.; Wilson, M.; Wang, X.; Shelton, J.; Shingara, J.; et al. The let-7 MicroRNA Represses Cell Proliferation Pathways in Human Cells. Cancer Res. 2007, 67, 7713–7722. [Google Scholar] [CrossRef] [Green Version]
- Kumar, M.S.; Erkeland, S.J.; Pester, R.E.; Chen, C.Y.; Ebert, M.S.; Sharp, P.A.; Jacks, T. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc. Natl. Acad. Sci. USA 2008, 105, 3903–3908. [Google Scholar] [CrossRef] [Green Version]
- Barh, D.; Malhotra, R.; Ravi, B.; Sindhurani, P. MicroRNA let-7: An emerging next-generation cancer therapeutic. Curr. Oncol. 2010, 17, 70–80. [Google Scholar] [CrossRef] [Green Version]
- Büssing, I.; Slack, F.; Grosshans, H. let-7 microRNAs in development, stem cells and cancer. Trends Mol. Med. 2008, 14, 400–409. [Google Scholar] [CrossRef]
- Garcia-Vazquez, R.; Gallardo Rincón, D.; Ruiz-García, E.; Meneses García, A.; Hernández De La Cruz, O.N.; Astudillo-De La Vega, H.; Isla-Ortiz, D.; Marchat, L.A.; Salinas-Vera, Y.M.; Carlos-Reyes, Á.; et al. let-7d-3p is associated with apoptosis and response to neoadjuvant chemotherapy in ovarian cancer. Oncol. Rep. 2018, 39, 3086–3094. [Google Scholar]
- Chen, Y.-N.; Ren, C.-C.; Yang, L.; Nai, M.-M.; Xu, Y.-M.; Zhang, F.; Liu, Y. MicroRNA let-7d-5p rescues ovarian cancer cell apoptosis and restores chemosensitivity by regulating the p53 signaling pathway via HMGA1. Int. J. Oncol. 2019, 54, 1771–1784. [Google Scholar] [CrossRef]
- Teague, E.M.; Print, C.G.; Hull, M.L. The role of microRNAs in endometriosis and associated reproductive conditions. Hum. Reprod. Update 2010, 16, 142–165. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Muralidhar, G.G.; Barbolina, M.V. The miR-200 Family: Versatile Players in Epithelial Ovarian Cancer. Int. J. Mol. Sci. 2015, 16, 16833–16847. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Park, S.-M.; Gaur, A.B.; Lengyel, E.; Peter, M.E. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genome Res. 2008, 22, 894–907. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bendoraite, A.; Knouf, E.C.; Garg, K.; Parkin, R.K.; Kroh, E.M.; O’Briant, K.; Ventura, A.P.; Godwin, A.K.; Karlan, B.Y.; Drescher, C.W.; et al. Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: Evidence supporting a mesothelial-to-epithelial transition. Gynecol. Oncol. 2010, 116, 117–125. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mongroo, P.S.; Rustgi, A.K. The role of the miR-200 family in epithelial-mesenchymal transition. Cancer Biol. Ther. 2010, 10, 219–222. [Google Scholar] [CrossRef]
- Zaravinos, A.; Radojičić, J.; Lambrou, G.I.; Volanis, D.; Delakas, D.; Stathopoulos, E.N.; Spandidos, D.A. Expression of miRNAs Involved in Angiogenesis, Tumor Cell Proliferation, Tumor Suppressor Inhibition, Epithelial-Mesenchymal Transition and Activation of Metastasis in Bladder Cancer. J. Urol. 2012, 188, 615–623. [Google Scholar] [CrossRef]
- Korpal, M.; Kang, Y. The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis. RNA Biol. 2008, 5, 115–119. [Google Scholar] [CrossRef] [Green Version]
- Cao, Q.; Lu, K.; Dai, S.; Hu, Y.; Fan, W. Clinicopathological and prognostic implications of the miR-200 family in patients with epithelial ovarian cancer. Int. J. Clin. Exp. Pathol. 2014, 7, 2392–2401. [Google Scholar]
- Liu, J.; Zhang, X.; Huang, Y.; Zhang, Q.; Zhou, J.; Zhang, X.; Wang, X. miR-200b and miR-200c co-contribute to the cisplatin sensitivity of ovarian cancer cells by targeting DNA methyltransferases. Oncol. Lett. 2019, 17, 1453–1460. [Google Scholar] [CrossRef] [Green Version]
- Yu, H.; Jove, R. The STATs of cancer—New molecular targets come of age. Nat. Rev. Cancer 2004, 4, 97–105. [Google Scholar] [CrossRef]
- Kong, H.; Zhang, Q.; Zeng, Y.; Wang, H.; Wu, M.; Zheng, T.; Zeng, Y.; Shi, H. Prognostic significance of STAT3/phosphorylated-STAT3 in tumor: A meta-analysis of literatures. Int. J. Clin. Exp. Med. 2015, 8, 8525–8539. [Google Scholar] [PubMed]
- Darnell, J.; Kerr, I.; Stark, G. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264, 1415–1421. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rosen, D.G.; Yang, G.; Bast, R.C.; Amin, H.M.; Lai, R.; Liu, J.; Mercado-Uribe, I.; Mercado-Uribe, I. The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer 2006, 107, 2730–2740. [Google Scholar] [CrossRef] [PubMed]
- Min, H.; Wei-Hong, Z. Constitutive activation of signal transducer and activator of transcription 3 in epithelial ovarian carcinoma. J. Obstet. Gynaecol. Res. 2009, 35, 918–925. [Google Scholar] [CrossRef]
- Permuth-Wey, J.; Fulp, W.J.; Reid, B.M.; Chen, Z.; Georgeades, C.; Cheng, J.Q.; Magliocco, A.; Chen, D.T.; Lancaster, J.M. STAT3 polymorphisms may predict an unfavorable response to first-line platinum-based therapy for women with advanced serous epithelial ovarian cancer. Int. J. Cancer 2016, 138, 612–619. [Google Scholar] [CrossRef] [Green Version]
- Coward, J.; Kulbe, H.; Chakravarty, P.; Leader, D.; Vassileva, V.; Leinster, D.A.; Thompson, R.; Schioppa, T.; Nemeth, J.; Vermeulen, J.; et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin. Cancer Res. 2011, 17, 6083–6096. [Google Scholar] [CrossRef] [Green Version]
- Yanaihara, N.; Hirata, Y.; Yamaguchi, N.; Noguchi, Y.; Saito, M.; Nagata, C.; Takakura, S.; Yamada, K.; Okamoto, A. Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary. Mol. Carcinog. 2016, 55, 832–841. [Google Scholar] [CrossRef]
- Rath, K.S.; Funk, H.M.; Bowling, M.C.; Richards, W.E.; Drew, A.F. Expression of soluble interleukin-6 receptor in malignant ovarian tissue. Am. J. Obstet. Gynecol. 2010, 203, 230.e1–230.e8. [Google Scholar] [CrossRef]
- Browning, L.; Patel, M.R.; Horvath, E.B.; Tawara, K.; Jorcyk, C.L. IL-6 and ovarian cancer: Inflammatory cytokines in promotion of metastasis. Cancer Manag. Res. 2018, 10, 6685–6693. [Google Scholar] [CrossRef] [Green Version]
- Isobe, A.; Sawada, K.; Kinose, Y.; Ohyagi-Hara, C.; Nakatsuka, E.; Makino, H.; Ogura, T.; Mizuno, T.; Suzuki, N.; Morii, E.; et al. Interleukin 6 Receptor Is an Independent Prognostic Factor and a Potential Therapeutic Target of Ovarian Cancer. PLoS ONE 2015, 10, e0118080. [Google Scholar] [CrossRef]
- Selvendiran, K.; Ahmed, S.; Dayton, A.; Kuppusamy, M.L.; Tazi, M.; Bratasz, A.; Tong, L.; Rivera, B.K.; Kálai, T.; Hideg, K.; et al. Safe and targeted anticancer efficacy of a novel class of antioxidant-conjugated difluorodiarylidenyl piperidones: Differential cytotoxicity in healthy and cancer cells. Free Radic. Biol. Med. 2010, 48, 1228–1235. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Selvendiran, K.; Tong, L.; Vishwanath, S.; Bratasz, A.; Trigg, N.J.; Kutala, V.K.; Hideg, K.; Kuppusamy, P. EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression. J. Biol. Chem. 2007, 282, 28609–28618. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Selvendiran, K.; Ahmed, S.; Dayton, A.; Ravi, Y.; Kuppusamy, M.L.; Bratasz, A.; Rivera, B.K.; Kálai, T.; Hideg, K.; Kuppusamy, P. HO-3867, a synthetic compound, inhibits the migration and invasion of ovarian carcinoma cells through downregulation of fatty acid synthase and focal adhesion kinase. Mol. Cancer Res. 2010, 8, 1188–1197. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Selvendiran, K.; Tong, L.; Bratasz, A.; Kuppusamy, M.L.; Ahmed, S.; Ravi, Y.; Trigg, N.J.; Rivera, B.K.; Kálai, T.; Hideg, K.; et al. Anticancer efficacy of a difluorodiarylidenyl piperidone (HO-3867) in human ovarian cancer cells and tumor xenografts. Mol. Cancer Ther. 2010, 9, 1169–1179. [Google Scholar] [CrossRef]
- Rath, K.S.; Naidu, S.K.; Lata, P.; Bid, H.K.; Rivera, B.K.; McCann, G.A.; Tierney, B.J.; Elnaggar, A.C.; Bravo, V.; Leone, G.; et al. HO-3867, a safe STAT3 inhibitor, is selectively cytotoxic to ovarian cancer. Cancer Res. 2014, 74, 2316–2327. [Google Scholar] [CrossRef] [Green Version]
- Selvendiran, K.; Ahmed, S.; Dayton, A.; Kuppusamy, M.L.; Rivera, B.K.; Kálai, T.; Hideg, K.; Kuppusamy, P. HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition. Cancer Biol. Ther. 2011, 12, 837–845. [Google Scholar] [CrossRef] [Green Version]
- Liu, Y.; Gong, W.; Yang, Z.Y.; Zhou, X.S.; Zhang, T.R.; Wei, X.; Ma, D.; Ye, F.; Gao, Q.L. Quercetin induces protective autophagy and apoptosis through ER stress via the p-STAT3/Bcl-2 axis in ovarian cancer. Apoptosis 2017, 22, 544–557. [Google Scholar] [CrossRef]
- Duchartre, Y.; Kim, Y.M.; Kahn, M. The Wnt signaling pathway in cancer. Crit. Rev. Oncol. Hematol. 2016, 99, 141–149. [Google Scholar] [CrossRef] [Green Version]
- Polakis, P. Wnt signaling in cancer. Cold Spring Harb. Perspect. Biol. 2012, 4, a008052. [Google Scholar] [CrossRef] [Green Version]
- Saran, U.; Arfuso, F.; Zeps, N.; Dharmarajan, A. Secreted frizzled-related protein 4 expression is positively associated with responsiveness to Cisplatin of ovarian cancer cell lines in vitro and with lower tumour grade in mucinous ovarian cancers. BMC Cell Biol. 2012, 13, 25. [Google Scholar] [CrossRef] [Green Version]
- Zeng, C.-M.; Chen, Z.; Fu, L. Frizzled Receptors as Potential Therapeutic Targets in Human Cancers. Int. J. Mol. Sci. 2018, 19, 1543. [Google Scholar] [CrossRef] [Green Version]
- Morin, P.J. Beta-catenin signaling and cancer. Bioessays 1999, 21, 1021–1030. [Google Scholar] [CrossRef]
- Palacios, J.; Gamallo, C. Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas. Cancer Res. 1998, 58, 1344–1347. [Google Scholar]
- Nagaraj, A.B.; Joseph, P.; Kovalenko, O.; Singh, S.; Armstrong, A.; Redline, R.; Resnick, K.; Zanotti, K.; Waggoner, S.; DiFeo, A. Critical role of Wnt/beta-catenin signaling in driving epithelial ovarian cancer platinum resistance. Oncotarget 2015, 6, 23720–23734. [Google Scholar] [CrossRef]
- Niiro, E.; Morioka, S.; Iwai, K.; Yamada, Y.; Ogawa, K.; Kawahara, N.; Kobayashi, H. Potential signaling pathways as therapeutic targets for overcoming chemoresistance in mucinous ovarian cancer. Biomed. Rep. 2018, 8, 215–223. [Google Scholar] [CrossRef] [Green Version]
- Vangipuram, S.D.; Buck, S.A.; Lyman, W.D. Wnt pathway activity confers chemoresistance to cancer stem-like cells in a neuroblastoma cell line. Tumor Biol. 2012, 33, 2173–2183. [Google Scholar] [CrossRef]
- Qian, L.; Xu, Z.; Zhang, W.; Wilson, B.; Hong, J.-S.; Flood, P.M. Sinomenine, a natural dextrorotatory morphinan analog, is anti-inflammatory and neuroprotective through inhibition of microglial NADPH oxidase. J. Neuroinflamm. 2007, 4, 23. [Google Scholar] [CrossRef] [Green Version]
- Wang, J.; Yang, Z.-R.; Dong, W.-G.; Zhang, J.-X.; Guo, X.-F.; Song, J.; Qiu, S. Cooperative inhibitory effect of sinomenine combined with 5-fluorouracil on esophageal carcinoma. World J. Gastroenterol. 2013, 19, 8292–8300. [Google Scholar] [CrossRef]
- Li, X.; Li, P.; Liu, C.; Ren, Y.; Tang, X.; Wang, K.; He, J. Sinomenine hydrochloride inhibits breast cancer metastasis by attenuating inflammation-related epithelial-mesenchymal transition and cancer stemness. Oncotarget 2017, 8, 13560–13574. [Google Scholar] [CrossRef] [Green Version]
- Lu, X.L.; Zeng, J.; Chen, Y.L.; He, P.M.; Wen, M.X.; Ren, M.D.; Hu, Y.N.; Lu, G.F.; He, S.Χ. Sinomenine hydrochloride inhibits human hepatocellular carcinoma cell growth in vitro and in vivo: Involvement of cell cycle arrest and apoptosis induction. Int. J. Oncol. 2013, 42, 229–238. [Google Scholar] [CrossRef]
- Li, H.; Lin, Z.; Bai, Y.; Chi, X.; Fu, H.; Sun, R.; Liu, M.; Liu, X.; Chen, L.; Shao, S. Sinomenine inhibits ovarian cancer cell growth and metastasis by mediating the Wnt/β-catenin pathway via targeting MCM2. RSC Adv. 2017, 7, 50017–50026. [Google Scholar] [CrossRef] [Green Version]
- Zhang, H.; Jiao, Y.; Shi, C.; Song, X.; Chang, Y.; Ren, Y.; Shi, X. Berbamine suppresses cell proliferation and promotes apoptosis in ovarian cancer partially via the inhibition of Wnt/beta-catenin signaling. Acta Biochim. Biophys. Sin. 2018, 50, 532–539. [Google Scholar] [CrossRef] [Green Version]
- Sun, Y.; Yao, T.; Li, H.; Peng, Y.; Zheng, J. In vitro and in vivo metabolic activation of berbamine to quinone methide intermediate. J. Biochem. Mol. Toxicol. 2017, 31, e21876. [Google Scholar] [CrossRef]
- Wang, G.-Y.; Lv, Q.-H.; Dong, Q.; Xu, R.-Z.; Dong, Q.-H. Berbamine induces Fas-mediated apoptosis in human hepatocellular carcinoma HepG2 cells and inhibits its tumor growth in nude mice. J. Asian Nat. Prod. Res. 2009, 11, 219–228. [Google Scholar] [CrossRef]
- Appleman, L.J. MET signaling pathway: A rational target for cancer therapy. J. Clin. Oncol. 2011, 29, 4837–4838. [Google Scholar] [CrossRef]
- Binju, M.; Padilla, M.A.; Singomat, T.; Kaur, P.; Rahmanto, Y.S.; Cohen, P.A.; Yu, Y. Mechanisms underlying acquired platinum resistance in high grade serous ovarian cancer—A mini review. Biochim. Biophys. Acta Gen. Subj. 2019, 1863, 371–378. [Google Scholar] [CrossRef]
- Birchmeier, C.; Birchmeier, W.; Gherardi, E.; Vande Woude, G.F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 2003, 4, 915–925. [Google Scholar] [CrossRef]
- Gherardi, E.; Birchmeier, W.; Birchmeier, C.; Woude, G.V. Targeting MET in cancer: Rationale and progress. Nat. Rev. Cancer 2012, 12, 89–103. [Google Scholar] [CrossRef]
- Bu, R.; Uddin, S.; Bavi, P.; Hussain, A.R.; Al-Dayel, F.; Ghourab, S.; Ahmed, M.; Al-Kuraya, K.S. HGF/c-Met pathway has a prominent role in mediating antiapoptotic signals through AKT in epithelial ovarian carcinoma. Lab. Investig. 2011, 91, 124–137. [Google Scholar] [CrossRef] [Green Version]
- Di Renzo, M.F.; Olivero, M.; Katsaros, D.; Crepaldi, T.; Gaglia, P.; Zola, P.; Sismondi, P.; Comoglio, P.M. Overexpression of theMET/HGF receptor in ovarian cancer. Int. J. Cancer 1994, 58, 658–662. [Google Scholar] [CrossRef]
- Koon, E.; Ma, P.; Salgia, R.; Welch, W.; Christensen, J.; Berkowitz, R.; Mok, S. Effect of a c-Met-specific, ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth, motility, and invasion. Int. J. Gynecol. Cancer 2008, 18, 976–984. [Google Scholar] [CrossRef]
- Sawada, K.; Radjabi, A.R.; Shinomiya, N.; Kistner, E.; Kenny, H.; Becker, A.R.; Turkyilmaz, M.A.; Salgia, R.; Yamada, S.D.; Woude, G.F.V.; et al. c-Met Overexpression Is a Prognostic Factor in Ovarian Cancer and an Effective Target for Inhibition of Peritoneal Dissemination and Invasion. Cancer Res. 2007, 67, 1670–1679. [Google Scholar] [CrossRef] [Green Version]
- Kim, H.J.; Yoon, A.; Ryu, J.Y.; Cho, Y.J.; Choi, J.J.; Song, S.Y.; Bang, H.; Lee, J.S.; Cho, W.C.; Choi, C.H.; et al. c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma. Sci. Rep. 2016, 6, 38502. [Google Scholar] [CrossRef] [Green Version]
- Wu, C.-C.; Weng, C.-S.; Hsu, Y.-T.; Chang, C.-L. Antitumor effects of BMS-777607 on ovarian cancer cells with constitutively activated c-MET. Taiwan. J. Obstet. Gynecol. 2019, 58, 145–152. [Google Scholar] [CrossRef]
- Dai, Y.; Siemann, D.W. BMS-777607, a Small-Molecule Met Kinase Inhibitor, Suppresses Hepatocyte Growth Factor-Stimulated Prostate Cancer Metastatic Phenotype In vitro. Mol. Cancer Ther. 2010, 9, 1554–1561. [Google Scholar] [CrossRef] [Green Version]
- De Luca, A.; Maiello, M.R.; D’Alessio, A.; Pergameno, M.; Normanno, N. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: Role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin. Ther. Targets 2012, 16, 17–27. [Google Scholar] [CrossRef]
- Yang, S.-H.; Sharrocks, A.D.; Whitmarsh, A.J. MAP kinase signalling cascades and transcriptional regulation. Gene 2013, 513, 1–13. [Google Scholar] [CrossRef]
- Vogelstein, B.; Papadopoulos, N.; Velculescu, V.E.; Zhou, S.; Diaz, L.A., Jr.; Kinzler, W. Cancer genome landscapes. Science 2013, 339, 1546–1558. [Google Scholar] [CrossRef]
- Ray, J.; Chen, Y.; Bhat, N.; Bieber, M.; Teng, N. Down Regulation of MAPK Signaling by Cytotoxic Human Monoclonal Antibody in Epithelial Ovarian Cancer. Gynecol. Oncol. 2017, 147, 220. [Google Scholar] [CrossRef]
- Bieber, M.M.; Twist, C.J.; Bhat, N.M.; Teng, N.N.H. Effects of human monoclonal antibody 216 on B-progenitor acute lymphoblastic leukemia in vitro. Pediatr. Blood Cancer 2007, 48, 380–386. [Google Scholar] [CrossRef]
- Duan, H.; Yan, Z.; Chen, W.; Wu, Y.; Han, J.; Guo, H.; Qiao, J. TET1 inhibits EMT of ovarian cancer cells through activating Wnt/beta-catenin signaling inhibitors DKK1 and SFRP2. Gynecol. Oncol. 2017, 147, 408–417. [Google Scholar] [CrossRef]
- Lim, W.; Song, G. Inhibitory effects of delphinidin on the proliferation of ovarian cancer cells via PI3K/AKT and ERK 1/2 MAPK signal transduction. Oncol. Lett. 2017, 14, 810–818. [Google Scholar] [CrossRef] [Green Version]
- Kang, H.-M.; Park, B.-S.; Kang, H.-K.; Park, H.-R.; Yu, S.-B.; Kim, I.-R. Delphinidin induces apoptosis and inhibits epithelial-to-mesenchymal transition via the ERK/p38 MAPK-signaling pathway in human osteosarcoma cell lines. Environ. Toxicol. 2018, 33, 640–649. [Google Scholar] [CrossRef]
- Ververidis, F.; Trantas, E.; Douglas, C.; Vollmer, G.; Kretzschmar, G.; Panopoulos, N. Biotechnology of flavonoids and other phenylpropanoid-derived natural products. Part I: Chemical diversity, impacts on plant biology and human health. Biotechnol. J. 2007, 2, 1214–1234. [Google Scholar] [CrossRef]
- Zamora-Ros, R.; Touillaud, M.; Rothwell, J.A.; Romieu, I.; Scalbert, A. Measuring exposure to the polyphenol metabolome in observational epidemiologic studies: Current tools and applications and their limits. Am. J. Clin. Nutr. 2014, 100, 11–26. [Google Scholar] [CrossRef]
- Snyder, R.D.; Gillies, P.J. Reduction of genistein clastogenicity in Chinese hamster V79 cells by daidzein and other flavonoids. Food Chem. Toxicol. 2003, 41, 1291–1298. [Google Scholar] [CrossRef]
- Ong, C.S.; Tran, E.; Nguyen, T.T.; Ong, C.K.; Lee, S.K.; Lee, J.J.; Ng, C.P.; Leong, C.; Huynh, H.; Nguyen, T.T.T. Quercetin-induced growth inhibition and cell death in nasopharyngeal carcinoma cells are associated with increase in Bad and hypophosphorylated retinoblastoma expressions. Oncol. Rep. 2004, 11, 727–733. [Google Scholar] [CrossRef]
- Lee, H.-J.; Wang, C.-J.; Kuo, H.-C.; Chou, F.-P.; Jean, L.-F.; Tseng, T.-H. Induction apoptosis of luteolin in human hepatoma HepG2 cells involving mitochondria translocation of Bax/Bak and activation of JNK. Toxicol. Appl. Pharmacol. 2005, 203, 124–131. [Google Scholar] [CrossRef]
- Shimizu, M.; Deguchi, A.; Lim, J.T.; Moriwaki, H.; Kopelovich, L.; Weinstein, I.B. (-)-Epigallocatechin Gallate and Polyphenon E Inhibit Growth and Activation of the Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor-2 Signaling Pathways in Human Colon Cancer Cells. Clin. Cancer Res. 2005, 11, 2735–2746. [Google Scholar] [CrossRef]
- Chen, D.; Daniel, K.G.; Chen, M.S.; Kuhn, D.J.; Landis-Piwowar, K.R.; Dou, Q.P. Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells. Biochem. Pharmacol. 2005, 69, 1421–1432. [Google Scholar] [CrossRef]
- Brusselmans, K.; Vrolix, R.; Verhoeven, G.; Swinnen, J.V. Induction of cancer cell apoptosis by flavonoids is associated with their ability to inhibit fatty acid synthase activity. J. Biol. Chem. 2005, 280, 5636–5645. [Google Scholar] [CrossRef] [Green Version]
- Plaumann, B.; Fritsche, M.; Rimpler, H.; Brandner, G.; Hess, R.D. Flavonoids activate wild-type p53. Oncogene 1996, 13, 1605–1614. [Google Scholar]
- Lim, W.; Jeong, W.; Song, G. Delphinidin suppresses proliferation and migration of human ovarian clear cell carcinoma cells through blocking AKT and ERK1/2 MAPK signaling pathways. Mol. Cell. Endocrinol. 2016, 422, 172–181. [Google Scholar] [CrossRef]
- Lim, W.-C.; Kim, H.; Kim, Y.-J.; Park, S.-H.; Song, J.-H.; Lee, K.H.; Lee, I.H.; Lee, Y.-K.; So, K.A.; Choi, K.-C.; et al. Delphinidin inhibits BDNF-induced migration and invasion in SKOV3 ovarian cancer cells. Bioorg. Med. Chem. Lett. 2017, 27, 5337–5343. [Google Scholar] [CrossRef]
- Delmas, D.; Lançon, A.; Colin, D.; Jannin, B.; Latruffe, N. Resveratrol as a chemopreventive agent: A promising molecule for fighting cancer. Curr. Drug Targets 2006, 7, 423–442. [Google Scholar] [CrossRef]
- Le Corre, L.; Chalabi, N.; Delort, L.; Bignon, Y.-J.; Bernard-Gallon, D.J.; Bernard-Gallon, D.J. Resveratrol and breast cancer chemoprevention: Molecular mechanisms. Mol. Nutr. Food Res. 2005, 49, 462–471. [Google Scholar] [CrossRef]
- Lin, H.-Y.; Delmas, D.; Vang, O.; Hsieh, T.-C.; Lin, S.; Cheng, G.-Y.; Chiang, H.-L.; Chen, C.E.; Tang, H.-Y.; Crawford, D.R.; et al. Mechanisms of ceramide-induced COX-2-dependent apoptosis in human ovarian cancer OVCAR-3 cells partially overlapped with resveratrol. J. Cell. Biochem. 2013, 114, 1940–1954. [Google Scholar] [CrossRef]
- Tyagi, A.; Singh, R.P.; Agarwal, C.; Siriwardana, S.; Sclafani, R.A.; Agarwal, R. Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR–Chk1/2–Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells. Carcinogenesis 2005, 26, 1978–1987. [Google Scholar] [CrossRef] [Green Version]
- Vergara, D.; Simeone, P.; Toraldo, D.; Del Boccio, P.; Vergaro, V.; Leporatti, S.; Pieragostino, D.; Tinelli, A.; de Domenico, S.; Alberti, S.; et al. Resveratrol downregulates Akt/GSK and ERK signalling pathways in OVCAR-3 ovarian cancer cells. Mol. BioSyst. 2012, 8, 1078–1087. [Google Scholar] [CrossRef]
- Steelman, L.S.; Stadelman, K.M.; Chappell, W.H.; Horn, S.; Basecke, J.; Cervello, M.; Nicoletti, F.; Libra, M.; Stivala, F.; Martelli, A.M.; et al. Akt as a therapeutic target in cancer. Expert Opin. Ther. Targets 2008, 12, 1139–1165. [Google Scholar] [CrossRef]
- Mills, G. The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. Semin. Oncol. 2001, 28, 125–141. [Google Scholar] [CrossRef]
- Cheng, J.Q.; Lindsley, C.W.; Cheng, G.Z.; Yang, H.; Nicosia, S.V. The Akt/PKB pathway: Molecular target for cancer drug discovery. Oncogene 2005, 24, 7482–7492. [Google Scholar] [CrossRef] [Green Version]
- Altomare, D.A.; Wang, H.Q.; Skele, K.L.; De Rienzo, A.; Klein-Szanto, A.J.; Godwin, A.K.; Testa, J.R. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 2004, 23, 5853–5857. [Google Scholar] [CrossRef] [Green Version]
- Cai, Y.; Tan, X.; Liu, J.; Shen, Y.; Wu, D.; Ren, M.; Huang, P.; Yu, D. Inhibition of PI3K/Akt/mTOR signaling pathway enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin in vitro. Chin. J. Cancer Res. 2014, 26, 564–572. [Google Scholar]
- Westfall, S.D.; Skinner, M.K. Inhibition of phosphatidylinositol 3-kinase sensitizes ovarian cancer cells to carboplatin and allows adjunct chemotherapy treatment. Mol. Cancer Ther. 2005, 4, 1764–1771. [Google Scholar] [CrossRef] [Green Version]
- Honig, A.; Hahne, J.C.; Meyer, S.; Kranke, P.; Häusler, S.; Diessner, J.; Dietl, J.; Engel, J.B. PI3K inhibitor D-116883 is effective in in vitro models of ovarian cancer. Anticancer. Res. 2012, 32, 2035–2041. [Google Scholar]
- Ding, Y.-H.; Zhou, Z.-W.; Ha, C.-F.; Zhang, X.-Y.; Pan, S.-T.; He, Z.-X.; Edelman, J.L.; Wang, D.; Yang, Y.-X.; Zhang, X.; et al. Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells. Drug Des. Dev. Ther. 2015, 9, 425–464. [Google Scholar]
- Falchook, G.; Coleman, R.L.; Roszak, A.; Behbakht, K.; Matulonis, U.; Ray-Coquard, I.; Sawrycki, P.; Duska, L.R.; Tew, W.; Ghamande, S.; et al. Alisertib in Combination with Weekly Paclitaxel in Patients with Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA Oncol. 2019, 5, e183773. [Google Scholar] [CrossRef] [Green Version]
- Tomao, F.; Panici, P.B.; Tomao, S. Paclitaxel and Alisertib in Recurrent Ovarian Cancer. JAMA Oncol. 2019, 5, 909–910. [Google Scholar] [CrossRef]
- Matulonis, U.A.; Sharma, S.; Ghamande, S.; Gordon, M.S.; Del Prete, S.A.; Ray-Coquard, I.; Kutarska, E.; Liu, H.; Fingert, H.; Zhou, X.; et al. Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Gynecol. Oncol. 2012, 127, 63–69. [Google Scholar] [CrossRef]
- Kakinuma, T.; Hwang, S.T. Chemokines, chemokine receptors, and cancer metastasis. J. Leukoc. Biol. 2006, 79, 639–651. [Google Scholar] [CrossRef]
- Cui, Z.Y.; Park, S.J.; Jo, E.; Hwang, I.H.; Lee, K.B.; Kim, S.W.; Kim, D.J.; Joo, J.C.; Hong, S.H.; Lee, M.G.; et al. Cordycepin induces apoptosis of human ovarian cancer cells by inhibiting CCL5-mediated Akt/NF-kappaB signaling pathway. Cell Death Discov. 2018, 4. [Google Scholar] [CrossRef] [Green Version]
Drug | Target | Clinical Trial ID | Number of Patients | Phase | Result |
---|---|---|---|---|---|
Birinapant | IAPs | NCT01681368 | 11 | 2 | SD = 2 (18.2 %) upto 4-5 months CR = 0 PR = 0 |
Birinapant | IAPs | NCT01940172 | 18 | 1 | PR = 1 SD = 4 |
DEBIO1143 | IAPs | NCT01930292 | 11 out of 31 with ovarian cancer | 1 | PR = 4 (36.4%) SD = 4 (36.4%) PD = 3 (27.2%) Terminated |
PRIMA-1MET | P53 | NCT02098343 | 200 | 1 & 2 | Ongoing |
Alisertib | Aurora kinase (PI3K/Akt/mTOR pathway) | NCT01091428 | 191 and 142 respectively | 1 & 2 | median PFS increased by 2 months |
Alisertib | Aurora kinase (PI3K/Akt/mTOR pathway) | NCT00853307 | 31 | 2 | CR = 3 (10%) PR = 4 (31%) SD = 7 (23%) PD = 12 (40%) NE = 5 (16.1%) |
Crizotinib | MET/ALK/ROS1 | NCT02465060 | 7/635 with MET amplification (ovarian cancer) | 2 | Ongoing |
Crizotinib | MET/ALK/ROS1 | NCT02568267 | 300 patients with different types of cancer | 2 | Ongoing |
Cabozantinib | MET | NCT00940225 | 70 | 2 | PR = 14 (20%) OS = 50% at 12 weeks PFS= 5.9 months |
Cabozantinib | MET | NCT02315430 | 13 | 2 | Results awaited |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Binju, M.; Amaya-Padilla, M.A.; Wan, G.; Gunosewoyo, H.; Suryo Rahmanto, Y.; Yu, Y. Therapeutic Inducers of Apoptosis in Ovarian Cancer. Cancers 2019, 11, 1786. https://doi.org/10.3390/cancers11111786
Binju M, Amaya-Padilla MA, Wan G, Gunosewoyo H, Suryo Rahmanto Y, Yu Y. Therapeutic Inducers of Apoptosis in Ovarian Cancer. Cancers. 2019; 11(11):1786. https://doi.org/10.3390/cancers11111786
Chicago/Turabian StyleBinju, Mudra, Monica Angelica Amaya-Padilla, Graeme Wan, Hendra Gunosewoyo, Yohan Suryo Rahmanto, and Yu Yu. 2019. "Therapeutic Inducers of Apoptosis in Ovarian Cancer" Cancers 11, no. 11: 1786. https://doi.org/10.3390/cancers11111786